Back to search
FDAFDA · Food and drugs·Recall number Z-0432-2022

VIDAS RUB IgG (RBG), REF 30226

Published January 5, 2022 · Recall initiated: September 22, 2021

Summary

FDA records medical device Class II recall Z-0432-2022, published January 5, 2022 and initiated September 22, 2021. Recalling firm: bioMerieux, Inc.; Status: Ongoing; Reported quantity: Three lots; Lot: UDI 03573026138585, Lot #: 1008694980, 1008700260, 1008828980. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
bioMerieux, Inc.
Distributor
US Nationwide distribution.
Lot
UDI 03573026138585, Lot #: 1008694980, 1008700260, 1008828980
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was VIDAS RUB IgG (RBG), REF 30226 recalled?

Yes. FDA published recall Z-0432-2022 on January 5, 2022. Reported hazard: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail